



ANALYST QUICK NOTES

New products, M&A announcements, management shakeups, earnings surprises. Whatever the news, you want to know what Argus thinks. Our Quick Notes fill this need by providing real-time analysis of current news about Argus-covered companies or other market-moving events. Please check back regularly for new Quick Notes. **Important disclaimer information is on the last page of this document.**

Gilead Sciences Inc. (NGS: GILD: HOLD)

Target Price: NM

David Toung

3/27/2017

Overview

- We highlight GILD today because we want to point out the impact on margins and earnings from declining sales of hep C drugs, which have worsened in 2017 after steep slides in 2016, according to prescription data. We point out heightened risk in the stock, based on our analysis.
- We published a note on March 24 lowering our estimates for adjusted EPS to \$8.14 from \$10.75 for 2017 establishing a new estimate of \$7.45 for 2018, both below consensus.
- Through the first two months of this year, U.S. Harvoni scripts have fallen 42% y/y on the retail side and 52% in the institutional channel, according to Symphony Health Solutions. The institutional channel is much larger than retail channel. By comparison, Harvoni sales fell 43% in 4Q16. Harvoni accounts for 30% of Gilead's product revenue.
- We point out that the prescription data does not include pricing data. Harvoni ASPs have eroded every year since 2015. The ASP was about \$31,000 for a 28-day supply when the drug was launched in 4Q14 and fell to \$15,000 in 2016, with prices in certain public programs such as Medicaid and federal 340B programs below \$10,000. We see additional erosion in 2017.
- When we combine falling prescriptions with price erosion, we can see Harvoni sales declining more than 50% in 1Q17.
- The falloff in prescriptions is even steeper for Sovaldi, another hep C product from Gilead.
- We had anticipated that the 3Q16 launch of Eplclusa, a pan-genotypic version of Gilead's hep C drug, would offset the declines in Harvoni and Sovaldi, but Eplclusa scripts seem to have peaked in 4Q16 and are declining so far this year.
- We see greater pressure on the operating margin as Gilead is increasing its spend on SG&A (to support marketing for its HIV drugs) and on R&D (as its key pipeline drugs in immunology and NASH are in Phase III trials). If approved, the new drugs are not likely to be launched until late 2019 or in 2020.
- So why we do we not find the valuation attractive in a stock that trades at 9.1-times our 2018 EPS estimate? Because we see more downside risk to hep C sales, margins and EPS.

- Could GILD use M&A to pull itself out of this situation? Hep C sales represented almost 50% of revenue (\$14.8 billion) in 2016. Any acquisition that could offset the hep C decline would have to be a huge deal and at big price tag (>\$50 billion), with a lot of deal and integration risk.
 - When we have access to prescription data for 2017 through the first two weeks of March and will can update our findings accordingly.
-

DISCLAIMER

This Note reflects the current thinking of an Argus analyst anticipating or responding to corporate earnings reports or other news relevant to covered companies. This Note may be an initial, real-time response to developments that are expected to impact stocks under coverage; as such, it does not imply that the information in it is correct as of any time after its preparation or that there has been no change in the business, financial condition, prospects, creditworthiness or status of a covered company. The views or opinions expressed in this Note are subject to change pending further analysis. This Note is produced and copyrighted by Argus Research Co., and any unauthorized use, duplication, redistribution or disclosure is prohibited by law and can result in prosecution. The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Argus makes no representation as to their timeliness, accuracy or completeness or for their fitness for any particular purpose. This Note is not an offer to sell or a solicitation of an offer to buy any security. The information presented in this Note is for general information only and does not specifically address individual investment objectives, financial situations or the particular needs of any specific person who may receive this Note. Investing in any security or investment strategies discussed may not be suitable for you and it is recommended that you consult an independent investment advisor. Nothing in this Note constitutes individual investment, legal or tax advice. Argus may issue or may have issued other reports that are inconsistent with or may reach different conclusions and opinions than those represented in this Note, and all opinions are reflective of judgments made on the original date of publication. Those reports may reflect the different assumptions, views and analytical methods of the analysts who prepared them and Argus is under no obligation to ensure that other reports are brought to the attention of any recipient of this Note or to update or keep current the information contained in other reports so that such information is consistent with, or not contrary to, the information contained in this Note. Argus Research is an independent investment research provider whose parent company, Argus Investors' Counsel, Inc., is registered with the U.S. Securities and Exchange Commission. Argus Investors' Counsel is a subsidiary of The Argus Research Group, Inc. Neither The Argus Research Group nor any affiliate is a member of the FINRA or the SIPC. Argus Research is not a registered broker dealer and does not have investment banking operations. Argus shall accept no liability for any loss arising from the use of this report, nor shall Argus treat all recipients of this report as customers simply by virtue of their receipt of this material. Investments involve risk and an investor may incur either profits or losses. Past performance should not be taken as an indication or guarantee of future performance. Argus has provided independent research since 1934. Argus officers, employees, agents and/or affiliates may have positions in stocks discussed in this report. No Argus officers, employees, agents and/or affiliates may serve as officers or directors of covered companies, or may own more than one percent of a covered company's stock.

Argus Investors' Counsel (AIC), a portfolio management business based in Stamford, Connecticut, is a customer of Argus Research Co. (ARC), based in New York. Argus Investors' Counsel pays Argus Research Co. for research used in the management of the AIC core equity strategy and model portfolio and UIT products, and has the same access to Argus Research Co. reports as other customers. However, clients and prospective clients should note that Argus Investors' Counsel and Argus Research Co., as units of The Argus Research Group, have certain employees in common, including those with both research and portfolio management responsibilities, and that Argus Research Co. employees participate in the management and marketing of the AIC core equity strategy and UIT and model portfolio products.
